Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in Recurrent BRCA Deficient Ovarian Cancer
NCT01661868Phase 2Withdrawn
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2012
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaparib in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Response Rates at 1 year. Planned start Aug 2012; status: withdrawn.
02
Drugs
olaparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT01661868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01661868.